The leading developer in thermal energy storage (“TES”) globally, Brenmiller, announced significant expansion in its project pipeline, marking a record level for the Company. As of May 1, 2024, Brenmiller boasts a project pipeline comprising 49 potential contracts at various…
BioNTech SE (Nasdaq: BNTX), referred to as “BioNTech” or the “Company,” held its Annual General Meeting (AGM) on May 17, 2024. The virtual assembly saw representation from 87.51% of the share capital. All 14 agenda items presented were approved by…
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders such as complement-mediated diseases, cancers, and addictive and compulsive disorders, has reported…
Baxter, a global leader in nutrition therapy, announced the U.S. FDA’s approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) for use in pediatric patients, including preterm and term neonates. Clinolipid, Baxter’s proprietary mixed oil lipid emulsion, provides essential…
Astellas Pharma Inc. will present new research from its innovative cancer therapies portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4. Sixteen abstracts will be showcased, including pivotal trial data supporting…
In its quarterly qualitative update, Lonza reported a softer Q1, with performance across H1 expected to align with the full-year 2024 trajectory. Lonza confirms its 2024 outlook, projecting flat sales growth in constant exchange rates (CER) and a Core EBITDA…
The Bayer Group’s performance in the first quarter of the year met expectations, according to CEO Bill Anderson. “First-quarter sales declined slightly versus the prior year. The Pharmaceuticals Division saw gains in growth and profitability, and the Crop Science Division…
Bristol Myers Squibb (NYSE: BMY) has provided an update on its Phase 3 CheckMate -73L trial, revealing that it did not achieve its primary endpoint of progression-free survival (PFS) in patients with unresectable, locally advanced stage III non-small cell lung…
CRISPR Therapeutics (Nasdaq: CRSP), a company dedicated to pioneering gene-based medicines for severe illnesses, has unveiled its financial performance for the first quarter ending March 31, 2024. CEO and Chairman of CRISPR Therapeutics, Dr. Samarth Kulkarni, highlighted the notable progress…
GlycoMimetics, Inc. (Nasdaq: GLYC), a biotechnology company specializing in advanced therapies for cancer and inflammatory conditions, has released the top-line results from its Phase 3 global pivotal trial of uproleselan involving 388 patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).…
Summary of Financial Highlights: In the first quarter of 2024, the company experienced significant growth across various metrics: Overall, the company demonstrated robust growth in revenues and product sales, despite challenges such as increased operating expenses and a shift in…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced its financial results for the first quarter ending March 31, 2024, along with notable recent business achievements. Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam, commented, “The year…